Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

NCT03599453 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Triple -Negative Breast Cancer
Estrogen Receptor Negative
HER2/Neu Negative
Anatomic Stage IV Breast Cancer AJCC
Progesterone Receptor Negative

Interventions

PROCEDURE: Biopsy
PROCEDURE: Chemokine Modulation Therapy
DRUG: Celecoxib
BIOLOGICAL: Recombinant Interferon Alfa-2b
DRUG: Rintatolimod
BIOLOGICAL: Pembrolizumab

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]